Jyong Biotech (MENS) Enterprise Value (2024 - 2025)
Jyong Biotech (MENS) posted quarterly Enterprise Value of -$253000.0 for Q4 2025, down 143.27% year-over-year from $584711.1 in Q4 2024, and down 87.41% quarter-over-quarter from -$135000.0 in Q2 2025.
Jyong Biotech (MENS) Enterprise Value (2024 - 2025) Analysis & Trends
Jyong Biotech's Enterprise Value history runs 2 years deep, the most recent figure standing at -$253000.0 for Q4 2025.
- In Q4 2025, Enterprise Value fell 143.27% year-over-year to -$253000.0; the TTM figure through Dec 2025 stood at -$253000.0 (down 143.27% YoY), while the FY2025 annual figure was -$253000.0, down 143.27% from the prior year.
- Enterprise Value for Q4 2025 stood at -$253000.0, down from -$135000.0 in the prior quarter.
- The five-year high for Enterprise Value was -$104000.0 in Q4 2024, with the low at -$253000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Jyong Biotech | 157.70 Mn | 157.70 Mn | - | -1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -253,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Dec 31, 2024 | -104,000.00 |